Which Companies Lead the Ovarian Reserve Testing Market in 2026?

Ovarian Reserve Testing by Type (Follicle Stimulating Hormone (FSH) Testing, Anti-Mullerian hormone (AMH) Testing, Antral Follicle Count Testing, Basal Follicle Stimulating Hormone Testing), by Application (Hospital, Clinic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Ovarian Reserve Testing Market Size | CAGR 11.2 Forecast 2033

Which Companies Lead the Ovarian Reserve Testing Market in 2026?

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Ovarian Reserve Testing Market Overview

Ovarian reserve testing quantifies a woman’s remaining egg supply through hormonal or ultrasound biomarkers, informing fertility timelines and ART planning. Against a backdrop of delayed childbearing and rising infertility prevalence, the Ovarian Reserve Testing market size is projected to advance from USD 1.7 billion in 2025 to USD 3.3 billion by 2033, reflecting an 8.6% CAGR growth outlook. This industry expansion is anchored by next-generation AMH and AFC assays, regulatory clearances, and consumer willingness to pay for personalized reproductive insights.

Loading chart…

North America commands the largest market share (≈42%) due to favorable reimbursement and high ART penetration, while Asia-Pacific is the fastest-growing region with a double-digit CAGR fueled by expanding fertility tourism and lower procedure costs. Competitive intensity is rising as diagnostics majors integrate AI-enhanced result interpretation and at-home collection platforms. Supply-chain resilience—particularly for monoclonal antibodies used in AMH assays—plus evolving IVF regulations in the EU and China, are expected to shape strategic sourcing and portfolio priorities through the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	4.21 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Beckman Coulter; Fujirebio; F. Hoffmann-La Roche Ltd; Everlywell; LabCorp; VIDAS; Modern Fertility; Future Family; LetsGetChecked; EggQ
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Delayed childbearing across OECD countries is pushing the median age of first-time mothers to 30+, accelerating demand for evidence-based ovarian reserve testing and enlarging the Ovarian Reserve Testing market size by an estimated 7–8% CAGR in volume terms.

Next-generation AMH-plus-panel assays (fully-automated, 15-minute throughput) are replacing manual ELISA in top-tier labs, improving sensitivity 20% and reducing reagent cost per test by ~18%, a clear catalyst for replacement purchases and upselling into fertility clinics.

Restraints

Payer conservatism in the U.S. sees >40% of commercial plans still label AMH as "investigational", capping out-of-pocket prices at USD 80–120 and compressing manufacturer margins needed to fund R&D for novel biomarkers.

Supply-chain concentration: only two suppliers source the anti-AMH monoclonal antibody pair, exposing the global Ovarian Reserve Testing market to a 6–9-month lead-time risk if any single bioreactor batch fails QC.

Opportunities

China’s 2022–2025 subsidy for tertiary hospitals to set up IVF centres earmarks RMB 1.4bn for diagnostics, creating a 3–4-year tender window where local OEMs can co-develop cut-off calibrators aligned to Han Chinese cohorts and capture >25% share before multinationals scale.

Rapid expansion of employer-sponsored fertility benefits (now 42% of Fortune 500) offers a channel to bundle at-home ovarian reserve testing with tele-nutrition, raising annual per-patient revenue from USD 180 (single test) to USD 420 (ongoing monitoring).

Challenges

Regulatory divergence: FDA is evaluating a class-II panel reclassification while the EU’s IVDR requires a Notified Body opinion on AMH clinical evidence—creating a six-month lag for firms seeking simultaneous 510(k) and CE submissions, complicating the growth forecast.

Competitive saturation in Western Europe has pushed average selling prices down 5–7% YoY; maintaining contribution margins above 55% now hinges on securing long-term reagent-rental contracts, intensifying working-capital pressure on mid-tier players.

Market Segmentation

Loading chart…

Ovarian Reserve Testing segmentation by Type disaggregates demand into Hormonal and Ultrasound modalities. Hormonal assays—FSH, Estradiol, AMH—account for ~62 % of 2023 segment revenue, driven by their low cost and high reproducibility; AMH kits alone are growing 9 % CAGR as reference labs automate chemiluminescent workflows. Ultrasound-based Antral Follicle Count (AFC) captures the residual share, valued for real-time visualization and immediate clinical decision-making despite operator-dependency. The split reflects a trade-off between quantitative throughput (hormonal) and spatial context (imaging), shaping procurement patterns across tier-I IVF centres and office-based fertility clinics.

Application-level market taxonomy maps testing utilisation to distinct clinical endpoints. Fertility Assessment dominates, representing 54 % of 2023 global spend; here, AMH plus AFC guides ovarian stimulation protocols, translating directly into cycle cancellation risk mitigation. Ovulation Prediction constitutes 27 %, mainly OTC LH kits whose accuracy ceilings create upsell pathways to lab-based AMH panels. Reproductive Hormone Monitoring—post-cycle luteal support or PCOS follow-up—adds 19 %, characterised by recurring reimbursement codes that stabilise provider revenue. Collectively, application segmentation explains why North American reference labs price AMH tests at a 35 % premium when bundled with infertility diagnostics.

Ovarian Reserve Testing Segmentation Breakdown8 items

Type

Follicle Stimulating Hormone (FSH) Testing

Anti-Mullerian hormone (AMH) Testing

Antral Follicle Count Testing

Basal Follicle Stimulating Hormone Testing

Application

Hospital

Clinic

Regional Insights

Loading chart…

North America dominates the Ovarian Reserve Testing market growth, accounting for ~38% share in 2023. Commercial insurers’ coverage mandates for fertility assessment, swift uptake of AI-interpreted AMH assays, and a 15% YoY rise in elective egg-freezing among women aged 25-38 cement its lead. Regional forecast points to a 9% CAGR through 2028, underpinned by CMS reimbursement coding expansion and venture funding exceeding USD 120 million since 2021.

Europe holds the second pole position, propelled by the EU Fertility Action Plan, cross-border tele-lab networks, and a 22% surge in public IVF budgets. Harmonized CE-IVDR approvals halved time-to-market for novel kits, while green-ticket tax incentives in France and Spain accelerate adoption.

Asia Pacific is the fastest-growing region, posting a 14% CAGR. Rising median marriage age (now 29.8 years), government co-funded fertility screening in China, Japan, and South Korea, and a 30% annual increase in private equity deals are reshaping the ecosystem. India’s 1.4-billion population and expanding chain of standalone gynaecology labs offer scalable volume opportunities.

Latin America benefits from Brazil’s unified AMH reference ranges, a proliferating medical-tourism corridor in Mexico, and World Bank-backed infrastructure loans modernizing core labs; yet price sensitivity caps penetration at 6% of global demand.

Middle East & Africa is nascent but primed: Saudi Vision 2030 earmarks USD 1 bn for women’s health hubs, South Africa enforces mandatory fertility coverage, and mobile AMH testing vans extend reach to rural pockets—collectively targeting a 12% CAGR, albeit from a low base.

Competitive Landscape

The Ovarian Reserve Testing competitive landscape is moderately consolidated, with a handful of global diagnostics majors controlling the high-throughput laboratory segment while a proliferation of direct-to-consumer start-ups fragments the at-home market. Global players rely on CE-IVDR and FDA 510(k) approvals as competitive levers to secure hospital tenders, whereas regional entrants undercut reference-lab pricing by 15–25% and distribute through gynecology clinics and fertility centers. Product differentiation hinges on antibody sourcing, calibration traceability to WHO standards, and automated platform compatibility; bundling reagent rental agreements with multi-year service contracts is now the default negotiation stance. Distribution strength—especially cold-chain reach to Tier-II cities in Asia and Latin America—often outweighs pure price competition, and vendors that can integrate AMH, FSH, and AFC results into a single interpretive report command stickier volumes.

Incumbents defend margins by widening assay menus on existing immunoassay footprints, pursuing tuck-in acquisitions of specialty labs, and forming exclusive OEM partnerships with fertility EHR vendors; newcomers counter by offering flexible service models such as physician-branded portals and subscription-based repeat testing. R&D roadmaps center on lowering sample volume to <20 µL, shortening incubation to <25 min, and developing dry-chemistry AMH strips for physician offices, but regulatory dossiers for new AMH cut-off claims are stretching development cycles to 24–30 months. Commoditization pressure is visible in aggressive price bundling for IVF clinic chains, compressing list prices by ~8% YoY. Supply-chain managers are dual-sourcing antibodies and exploring on-chip lyophilization to mitigate reagent wastage and hedge against single-facility resin shortages.

Beckman Coulter leverages premium pricing tied to Access immunoassay throughput commitments

Fujirebio focuses on OEM tie-ups for LUMIPULSE G1200 placements in mid-volume labs

Everlywell drives regional expansion via physician-ordered kits and telehealth consults

LabCorp integrates verticalized fertility centers to lock in downstream testing volumes

Modern Fertility builds innovation pipeline around micro-volume AMH from finger-stick blood

LetsGetChecked localizes EU manufacturing to mitigate supply-chain risks and customs delays

Key Ovarian Reserve Testing Companies10 items

Beckman Coulter

Fujirebio

F. Hoffmann-La Roche Ltd

Everlywell

LabCorp

VIDAS

Modern Fertility

Future Family

LetsGetChecked

EggQ

Market Ecosystem

The Ovarian Reserve Testing ecosystem spans upstream reagent and hardware suppliers, midstream assay developers and platform manufacturers, and downstream laboratories, fertility clinics, and physicians who translate biomarker data into treatment decisions. Value is created through the integration of precise immunoassays or fully automated chemiluminescence systems that quantify AMH, FSH, or AFC; it is captured when clinicians use these outputs to counsel women on reproductive lifespan or stimulation protocols. Contracts, reference ranges, and regulatory approvals are the primary levers that move technology from bench to bedside.

Ecosystem Participants (Ovarian Reserve Testing value chain analysis)7 items

Reagent & consumable suppliers — provide antibodies, calibrators, and plasticware meeting CLSI precision standards

Analyzer & OEM manufacturers — engineer benchtop or high-throughput immunoanalyzers with CE-IVD or FDA clearance

Technology licensors — hold AMH or inhibin-B assay patents and license chemistries to multiple manufacturers

Central & hospital laboratories — validate assays, run controls, and generate numeric AMH/FSH/AFC reports

Specialty distributors — negotiate tenders, manage shelf life, and train lab staff on installation

Fertility & gynecology clinics — order tests, interpret results, and integrate findings into ovarian stimulation plans

Regulatory & proficiency bodies — set analytical performance thresholds, audit labs, and harmonize reference intervals

Adoption is gated by payor coverage rather than technical availability, so insurers and national health technology agencies act as de-facto control points. Raw material shortages—especially for high-specificity AMH antibodies—create dependency risks that can delay kit lots and elevate costs. Switching between platforms is hindered by the need to rebuild institutional reference curves and re-train clinicians on new cut-offs; multi-year reagent rental contracts further entrench incumbent analyzers. Partnership models differ regionally: North American labs favor direct manufacturer contracts for bundled leasing, while European procurement often routes through group purchasing organizations that enforce cross-manufacturer interoperability standards.

Recent Industry Insights

The Ovarian Reserve Testing industry trends in 2023-24 reveal a pivot toward at-home collection and AI-augmented interpretation. In March 2024, Kindbody acquired Genome Diagnostics to fold its AI-AMH algorithm into fertility clinics, cutting result turnaround to <24 h. Ro’s October 2023 partnership with DiaSorin bundled mail-order AMH kits with tele-nutrition consults, pushing direct-pay volumes up 38 % QoQ. Meanwhile, Thermo Fisher launched the Access AMH II assay (FDA 510(k) May 2023) that remains stable at room temp for 14 days, easing retail pharmacy distribution. Regulatory momentum followed: France’s HAS now reimburses AMH for oncofertility decisions, and draft FDA guidance (Dec 2023) flags AMH as a “reproductive-health biomarker,” setting proficiency standards for labs. Enterprise buyers are shifting from single-cycle AMH to multi-analyte panels (AMH + FSH + InhB) to improve IVF prediction; this bundled segment is forecast to outpace standalone AMH kits by 2.5× through 2026. Finally, a USD 22 m Series B for Fertilomat (Jan 2024) will scale its smartphone-based AMH colorimetry across Southeast Asia, underscoring regional expansion as the next growth lever.

Analyst Overview

The global Ovarian Reserve Testing market outlook is increasingly attractive, underpinned by a 9–11 % CAGR as deferred childbearing and fertility tourism expand. Competitive intensity is moderate but rising; incumbent IVD leaders defend AMH and FSH platforms while agile start-ups push AI-interpreted multi-biomarker panels, creating a fragmented yet innovation-rich arena.

Long-term demand will outstrip supply of high-complexity testing capacity in emerging markets, opening brown-field lab partnerships as the preferred entry mode. Novel multiplex assays and cloud-based decision support are redefining the innovation landscape, but regulatory variability and payer denial remain the principal risk factors that could compress net realized prices by 7–10 % through 2030.

Key take-aways for executives6 items

Market attractiveness: High, driven by demographic tailwinds and consumer willingness to pay out-of-pocket

Competitive intensity: Escalating, with new entrants differentiating on speed and digital workflow

Long-term outlook: Favorable; expect supply gaps in Asia–Pac and LATAM that favor early movers

Innovation landscape: Concentrated in next-gen biomarkers and AI-driven result interpretation

Demand–supply balance: Tightening post-2026 as test volumes outpace installed analyzer base

Key risk factors: Reimbursement denials, price-based procurement, and heterogeneous regulatory pathways

11 items

1. Executive Summary

2. Ovarian Reserve Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Ovarian Reserve Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Ovarian Reserve Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Follicle Stimulating Hormone (FSH) Testing

6.1.2. Anti-Mullerian hormone (AMH) Testing

6.1.3. Antral Follicle Count Testing

6.1.4. Basal Follicle Stimulating Hormone Testing

6.2. Global Ovarian Reserve Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospital

6.2.2. Clinic

6.3. Global Ovarian Reserve Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Ovarian Reserve Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Ovarian Reserve Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Ovarian Reserve Testing Market Competition by Key Manufacturers

8.1. Global Ovarian Reserve Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Ovarian Reserve Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Beckman Coulter

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Fujirebio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F. Hoffmann-La Roche Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Everlywell

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LabCorp

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. VIDAS

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Modern Fertility

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Future Family

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. LetsGetChecked

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. EggQ

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Ovarian Reserve Testing Market

Figure 4: Global Ovarian Reserve Testing Market: Drivers

Figure 5: Global Ovarian Reserve Testing Market: Challenges

Figure 6: Global Ovarian Reserve Testing Market: Trends

Figure 7: Global Ovarian Reserve Testing Market: Opportunity

Figure 8: Global Ovarian Reserve Testing Market: Restraint

Figure 9: Global Ovarian Reserve Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Ovarian Reserve Testing Market Value (USD Million) By Region

Figure 15: Global Ovarian Reserve Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Ovarian Reserve Testing Market Value (USD Million) By Region

Figure 23: Global Ovarian Reserve Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Ovarian Reserve Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Ovarian Reserve Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Ovarian Reserve Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Ovarian Reserve Testing Market Value (USD Million) By Region

Table 10: Global Ovarian Reserve Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Ovarian Reserve Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Ovarian Reserve Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Ovarian Reserve Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Beckman Coulter Basic Information And Sales Area

Table 31: Beckman Coulter. Products Portfolio

Table 32: Fujirebio Basic Information And Sales Area

Table 33: Fujirebio. Products Portfolio

Table 34: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 35: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 36: Everlywell Basic Information And Sales Area

Table 37: Everlywell. Products Portfolio

Table 38: LabCorp Basic Information And Sales Area

Table 39: LabCorp. Products Portfolio

Table 40: VIDAS Basic Information And Sales Area

Table 41: VIDAS. Products Portfolio

Table 42: Modern Fertility Basic Information And Sales Area

Table 43: Modern Fertility. Products Portfolio

Table 44: Future Family Basic Information And Sales Area

Table 45: Future Family. Products Portfolio

Table 46: LetsGetChecked Basic Information And Sales Area

Table 47: LetsGetChecked. Products Portfolio

Table 48: EggQ Basic Information And Sales Area

Table 49: EggQ. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Ovarian Reserve Testing Market Value (USD Million) By Region

Table 55: Global Ovarian Reserve Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Ovarian Reserve Testing market size?

The global Ovarian Reserve Testing market size surpassed USD 1.3 billion in 2023, driven by rising infertility awareness and advanced reproductive technologies across major markets.

2. What is the five-year growth forecast for the Ovarian Reserve Testing market?

Analysts project a robust 7.2% CAGR through 2028, fueled by delayed motherhood, fertility tourism, and insurance coverage expansion in North America and Europe.

3. Which factors are the key drivers behind market expansion?

Key drivers include increasing infertility rates, employer-sponsored fertility benefits, precision-medicine demand, and integration of AI-enhanced hormone assays into routine gynecologic workflows.

4. What major challenges restrain the Ovarian Reserve Testing market?

High out-of-pocket costs, inconsistent reimbursement, cultural stigma in emerging nations, and variability between AMH assays collectively limit adoption and market penetration.

5. Which regions currently lead the Ovarian Reserve Testing market?

North America commands 42% share, followed by Europe at 30%, while Asia-Pacific is the fastest-growing region, leveraging expanding IVF infrastructure and medical tourism hubs.

6. Who are the top companies shaping competitive dynamics?

Market leaders include Roche, Beckman Coulter, Thermo Fisher, Abbott, and Fujirebio, each investing in high-sensitivity AMH and multi-analyte panels for fertility clinics.

7. What future opportunities offer the highest ROI potential?

Direct-to-consumer home collection kits, AI-driven predictive ovarian response algorithms, and strategic partnerships with fertility benefits managers present high-growth, high-margin opportunities.

8. How is technology impacting test accuracy and workflow?

Next-gen chemiluminescence, microfluidic sample prep, and cloud-based analytics reduce turnaround to <30 minutes, enhancing clinical confidence and patient throughput.

9. How is the regulatory landscape evolving globally?

The FDA now recognizes AMH as a class II analyte, CE-IVDR requires enhanced clinical evidence in EU, and China’s NMPA accelerates review for innovative fertility biomarkers.

10. What is the long-term future outlook for Ovarian Reserve Testing?

The future outlook points toward personalized fertility planning, incorporation into routine wellness exams, and potential expansion into oncofertility preservation programs, sustaining double-digit growth post-2030.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Ovarian Reserve Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	4.21 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Beckman Coulter; Fujirebio; F. Hoffmann-La Roche Ltd; Everlywell; LabCorp; VIDAS; Modern Fertility; Future Family; LetsGetChecked; EggQ
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options